The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Aralez Pharmaceuticals Inc closed at $1.84.

Over the last five days, shares have lost 8.91% and are down 68.87% for the last year to date. This security has underperformed the S&P TSX by 74.78% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$1.48
Updated May 26 3:58 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-133.92%

Aralez Pharmaceuticals Inc has a net profit margin of -133.92%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:Industry:

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue26201413
Total other revenue--------
Total revenue26201413
Gross profit2318109
Total cost of revenue3333
Total operating expense47483330
Selling / general / administrative31332523
Research & development0121
Depreciation / amortization9722
Interest expense (income), net operating--------
Unusual expense (income)--4----
Other operating expenses, total41----
Operating income-21-28-20-17
Interest income (expense), net non-operating-7-50-1
Gain (loss) on sale of assets--------
Other--------
Income before tax-27-32-20-18
Income after tax-27-31-21-17
Income tax, total1-10-1
Net income-27-31-21-17
Total adjustments to net income--------
Net income before extra. items-27-31-21-17
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-27-31-21-17
Inc. avail. to common incl. extra. items-27-31-21-17
Diluted net income-27-31-21-17
Dilution adjustment--------
Diluted weighted average shares66666564
Diluted EPS excluding extraordinary itemsvalue per share-0.42-0.47-0.32-0.27
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.42-0.43-0.32-0.27